| Products
|
Bebtelovimab
(Eli Lilly)
|
Molnupiravir
(Merck)
|
Paxlovid
(Pfizer)
|
Tixagevimab/Cilgavimab
(EVUSHELD)
|
| Authorized Use(s)
|
Treatment of mild to moderate symptoms
|
Treatment of mild to moderate symptoms
|
Treatment of mild to moderate symptoms
|
Pre-exposure prevention for immunocompromised individuals
|
| Age Eligibility
|
Ages 12 years and older
|
Ages 18 and older
|
Ages 12 years and older
|
Ages 12 years and older
|
| Weight Eligibility
|
88 pounds or more
|
No weight requirement
|
88 pounds or more
|
88 pounds or more
|
| Other Criteria for Treatment
|
Test Positive for SARS-CoV-2
Be within 7 days of the start of symptoms
Not be hospitalized
Not require oxygen and/or respiratory support
|
Test Positive for SARS-CoV-2
Be within 5 days of the start of symptoms
Not be hospitalized
|
Test Positive for SARS-CoV-2
Be within 5 days of the start of symptoms
Not be hospitalized
|
Not currently infected with SARS-CoV-2
Have not had a known recent exposure to an infected individual with SARS-CoV-2
|
| Other Criteria for Prevention
|
|
|
|
Must have moderate to severe immune compromise due to a medical condition diagnosed by a health care provider
|
| Letter of Authorization
|
Bebtelovimab Letter of Authorization (EUA)
|
Molnupiravir EUA Letter of Authorization
|
Paxlovid EUA Letter of Authorization
|
Evusheld EUA Letter of Authorization (EUA)
|
| EUA Fact Sheet
|
Bebtelovimab Provider Fact Sheet
|
Molnupiravir Provider Fact Sheet
|
Paxlovid Provider Fact Sheet
|
Evusheld Provider Fact Sheet
|